R Donken1,2, A J King1, J A Bogaards1,3, P J Woestenberg1,4, C J L M Meijer2, H E de Melker1. 1. Center for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven. 2. Department of Pathology, VU University Medical Center, Amsterdam. 3. Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam. 4. Care and Public Health Research Institute, Maastricht University Medical Center, Maastricht, the Netherlands.
Abstract
Background: Monitoring vaccine effectiveness (VE) in vaccination programs is of importance for assessing the impact of immunization. This study aimed to estimate the VE of the bivalent human papillomavirus (HPV) vaccine against incident and 12-month persistent infections up to 6 years after vaccination. Methods: In 2009-2010, girls eligible for the vaccination catch-up campaign (ie, those aged 14-16 years) were enrolled into a prospective cohort. Annually, participants completed a questionnaire and submitted a self-collected vaginal swab sample for HPV testing by the SPF10-LiPA25 assay. We compared sociodemographic characteristics and infection rates between vaccinated and unvaccinated girls. The VE was adjusted for characteristics related to HPV vaccination status. We used combined end points for VE estimation. Results: In total, 1635 women, of whom 54% were fully vaccinated, were included for VE estimation. The adjusted VE against HPV16 and 18 persistent infections amounted to 97.7% (95% confidence interval [CI], 83.5%-99.7%). We found a VE against HPV31, 33, and 45 persistent infections of 61.8% (95% CI, 16.7%-82.5%). We found no indications that the protection against vaccine or cross-protective types changes over time. Conclusion: Our findings of nearly full protection against vaccine-type persistent infections and significant cross-protection to nonvaccine types in a population-based cohort study confirm the effectiveness of the bivalent HPV vaccine as estimated in trials. We found no indications for waning protection up to 6 years after vaccination.
Background: Monitoring vaccine effectiveness (VE) in vaccination programs is of importance for assessing the impact of immunization. This study aimed to estimate the VE of the bivalent human papillomavirus (HPV) vaccine against incident and 12-month persistent infections up to 6 years after vaccination. Methods: In 2009-2010, girls eligible for the vaccination catch-up campaign (ie, those aged 14-16 years) were enrolled into a prospective cohort. Annually, participants completed a questionnaire and submitted a self-collected vaginal swab sample for HPV testing by the SPF10-LiPA25 assay. We compared sociodemographic characteristics and infection rates between vaccinated and unvaccinated girls. The VE was adjusted for characteristics related to HPV vaccination status. We used combined end points for VE estimation. Results: In total, 1635 women, of whom 54% were fully vaccinated, were included for VE estimation. The adjusted VE against HPV16 and 18 persistent infections amounted to 97.7% (95% confidence interval [CI], 83.5%-99.7%). We found a VE against HPV31, 33, and 45 persistent infections of 61.8% (95% CI, 16.7%-82.5%). We found no indications that the protection against vaccine or cross-protective types changes over time. Conclusion: Our findings of nearly full protection against vaccine-type persistent infections and significant cross-protection to nonvaccine types in a population-based cohort study confirm the effectiveness of the bivalent HPV vaccine as estimated in trials. We found no indications for waning protection up to 6 years after vaccination.
Authors: Joseph E Tota; Frank Struyf; Joshua N Sampson; Paula Gonzalez; Martin Ryser; Rolando Herrero; John Schussler; Naveen Karkada; Ana Cecilia Rodriguez; Nicolas Folschweiller; Carolina Porras; Mark Schiffman; John T Schiller; Wim Quint; Aimée R Kreimer; Cosette M Wheeler; Allan Hildesheim Journal: J Natl Cancer Inst Date: 2020-08-01 Impact factor: 13.506
Authors: Sabrina H Tsang; Joshua N Sampson; John Schussler; Carolina Porras; Sarah Wagner; Joseph Boland; Bernal Cortes; Douglas R Lowy; John T Schiller; Mark Schiffman; Troy J Kemp; Ana Cecilia Rodriguez; Wim Quint; Mitchell H Gail; Ligia A Pinto; Paula Gonzalez; Allan Hildesheim; Aimée R Kreimer; Rolando Herrero Journal: J Natl Cancer Inst Date: 2020-10-01 Impact factor: 13.506
Authors: Nicolas Folschweiller; Ulrich Behre; Marc Dionne; Paolo Durando; Susanna Esposito; Linda Ferguson; Murdo Ferguson; Peter Hillemanns; Shelly A McNeil; Klaus Peters; Brian Ramjattan; Tino F Schwarz; Khuanchai Supparatpinyo; Pemmaraju V Suryakirian; Michel Janssens; Philippe Moris; Annabelle Decreux; Sylviane Poncelet; Frank Struyf Journal: J Infect Dis Date: 2019-05-05 Impact factor: 5.226
Authors: Petra J Woestenberg; Johannes A Bogaards; Audrey J King; Suzan Leussink; Marianne Ab van der Sande; Christian Jpa Hoebe; Birgit Hb van Benthem Journal: Int J Cancer Date: 2018-12-21 Impact factor: 7.396
Authors: Johannes A Bogaards; Pascal van der Weele; Petra J Woestenberg; Birgit H B van Benthem; Audrey J King Journal: J Infect Dis Date: 2019-08-30 Impact factor: 5.226
Authors: Pascal van der Weele; Martijn Breeuwsma; Robine Donken; Elske van Logchem; Naomi van Marm-Wattimena; Hester de Melker; Chris J L M Meijer; Audrey J King Journal: PLoS One Date: 2019-03-04 Impact factor: 3.240